Patterns of antihypertensive use among patients in the US Department of Defense Database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker

Clinical Therapeutics

Volumn 19, Issue 6, 1997, Pages 1433-1445

  Okano, Gary J ^a,b   Rascati, Karen L ^b   Wilson, James P ^b   Remund, Daniel D ^c   Grabenstein, John D ^d   Brixner, Diana I ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Pharmacoeconomic Center   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ACE inhibitors; Antihypertensives; Calcium channel blockers; Drug utilization

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; DATA BASE; DRUG USE; HUMAN; HYPERTENSION; REVIEW; UNITED STATES;

EID: 0031409103     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80017-3     Document Type: Note

References (16)

1. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
2. McLaughlin TJ. Hypertension disease management in organized systems of care. Spectrum. 1995;1-9.
3. World Hypertension League. WHL workshop: Economics of hypertension control. World Hypertens News. 1991;20:4.
4. Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population. BMJ. 1995;311:293-295.
5. Sasane R, Brixner D, Goodwin W. Antihypertensive drug utilization review - a step approach. J Managed Care Pharm. 1997;3:299. Abstract.
6. Bobal E, O'Connor DL, Keefe J. Trends in the treatment of hypertension within managed care organizations: A national survey of HMO pharmacy directors. J Managed Care Pharm. 1997;3:317-322.
7. Skaer TL, Sclar DA, Robison LM, et al. Effects of pharmaceutical formulation for diltiazem on health care expenditures. Clin Ther. 1993;15:905-911.
8. Sclar DA, Skaer TL, Robison LM, et al. Antihypertensive pharmacotherapy: Economic outcomes in a health maintenance organization. Curr Ther Res. 1994;55: 1056-1066.
9. Sica DA. Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy? Drugs. 1994;48:16-24.
10. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med. 1984;100: 258-268.
11. Dannenberg AL, Garrison RJ, Kannel WB. Incidence of hypertension in the Framingham Study. Am J Public Health. 1988; 78:676-679.
12. Cornoni-Huntley J, LaCroix AZ, Havlik RJ. Race and sex differentials in the impact of hypertension in the United States. The National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med. 1989;149: 780-788.
13. Alderman MH, Madhavan S, Cohen H. Antihypertensive drug therapy. The effects of JNC criteria on prescribing patterns and patient status through the first year. Am J Hypertens. 1996;9:413-418.
14. Psaty BM, Koepsell TD, Yanez ND, et al. Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992. An effect of the major clinical trials on clinical practice? JAMA. 1995;273:1436-1438.
15. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
16. Emerging Issues in Pharmaceutical Cost Containment. Reston, Virginia: National Pharmaceutical Council; 1992;2:1-16.